News | October 13, 2008

Data Indicates Abbott's XIENCE V Stent Patients Are at Lower Risk of Death, Heart Attack

October 13, 2008 — Data from an independent meta-analysis of Abbott Vascular’s SPIRIT II and SPIRIT III randomized clinical trials demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System continues to deliver clinically significant benefits for patients compared to the TAXUS paclitaxeleluting coronary stent system out to two years, said Abbott.

In this meta-analysis, which included patients from the U.S., Europe and Asia-Pacific, XIENCE V demonstrated clinical superiority to TAXUS in the endpoints of target vessel failure (TVF) and major adverse cardiac events (MACE) at two years.

XIENCE V also demonstrated significantly lower clinical events rates than TAXUS in the key efficacy (target lesion revascularization) and safety (cardiac death or heart attack) components of MACE at two years. The results are being presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, at TCT 2008.

The meta-analysis of 1,302 patients from the SPIRIT II and SPIRIT III trials demonstrated the following key results for XIENCE V at two years:

• A clinically significant 31 percent reduction in the risk of ischemia-driven Target Vessel Failure (TVF, cardiac events related to the treated vessel) compared to TAXUS (10.4 percent for XIENCE V vs. 14.7 percent for TAXUS, p-value=0.03)*. TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

• A clinically significant 45 percent reduction in the risk of ischemia-driven major adverse cardiac events (MACE) compared to TAXUS (7.1 percent for XIENCE V vs. 12.3 percent for TAXUS, p-value=0.001)°Ø. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (TLR driven by lack of blood supply).

• An observed 28 percent reduction in the risk of all-cause death compared to TAXUS (2.4 percent for XIENCE V vs. 3.3 percent for TAXUS, p-value=0.36)*.

• An observed 28 percent reduction in the risk of cardiac death compared to TAXUS (0.9 percent for XIENCE V vs. 1.3 percent for TAXUS, p-value=0.56)*.

• A clinically significant 45 percent reduction in the risk of heart attack (MI) compared to TAXUS (3.1 percent for XIENCE V vs. 5.6 percent for TAXUS, p-value=0.03)*.

• A clinically significant 39 percent reduction in the risk of all-cause death or heart attack (MI) compared to TAXUS (5.1 percent for XIENCE V vs. 8.3 percent for TAXUS, p-value=0.03)*.

• A clinically significant 41 percent reduction in the risk of cardiac death or heart attack (MI) compared to TAXUS (3.8 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.04)*.

• A clinically significant 41 percent reduction in the risk of ischemia-driven target lesion revascularization (ID-TLR) compared to TAXUS (4.1 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.03)*.

* - Event rates are based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

• Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

Also presented during TCT 2008, a variety of subgroup analyses from the SPIRIT III trial demonstrated observational evidence of strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. The results consistently favored XIENCE V compared to TAXUS at two years across multiple subgroups examined, including patients with small vessels and multi-vessel patients. In diabetic patients, the analysis showed there were no observed differences between XIENCE V and TAXUS at two years. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as the sample sizes were too small to draw firm conclusions.

For more information: www.abbott.com

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init